Atorvastatin effects on SREBF1a and SCAP gene expression in mononuclear cells and its relation with lowering-lipids response

Clinica Chimica Acta

Volumn 393, Issue 2, 2008, Pages 119-124

  Arazi, Simone Sorkin ^a   Genvigir, Fabiana Dalla Vecchia ^a   Willrich, Maria Alice Vieira ^a   Hirata, Mario Hiroyuki ^a   Dorea, Egidio Lima ^a   Bernik, Marcia ^a   Hirata, Rosario Dominguez Crespo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Gene expression; Mononuclear cells; Pharmacogenomics; SCAP; SREBF1a; Statins

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; STEROL REGULATORY ELEMENT BINDING PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SCAP; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CELL STRAIN HEPG2; DOWN REGULATION; DRUG EFFECT; FEMALE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENOTYPE; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; QUANTITATIVE GENETICS; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STATISTICAL SIGNIFICANCE; TRANSCRIPTION REGULATION; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; BASE SEQUENCE; DNA PRIMERS; FEMALE; GENE EXPRESSION REGULATION; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPIDS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; POLYMERASE CHAIN REACTION; PYRROLES; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 44449133160     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2008.03.031     Document Type: Article

References (41)

1. Horton J.D., Goldstein J.L., and Brown M.S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109 (2002) 1125-1131
2. Weber L.W., Boll M., and Stampfl A. Maintaining cholesterol homeostasis: sterol regulatory element-binding protein. World J Gastroenterol 10 (2004) 3081-3087
3. Hua X., Wu J., Goldstein J.L., Brown M.S., and Hobbs H.H. Structure of the human gene encoding sterol regulatory element binding protein-1 (SREBF1) and localization of SREBF1 and SREBF2 to chromosomes 17p11.2 and 22q13. Genomics 25 (1995) 667-673
4. McPherson R., and Gautheier A. Molecular regulation of SREBP function: the Insig-SCAP connection and isoform-specific modulation of lipid synthesis. Biochem Cell Biol 82 (2004) 201-211
5. Sakai J., Nohturfft A., Chen D., Ho Y.K., Brown M.S., and Goldstein J.L. Identification of complexes between the COOH-terminal domains of sterol regulatory element binding proteins (SREBPs) and SREBP cleavage-activating protein. J Biol Chem 272 (1997) 20213-20221
6. Flury I., Garza R., Shearer A., Rosen J., Cronin S., and Hampton R.Y. INSIG: a broadly conserved transmembrane chaperone for sterol-sensing domain proteins. EMBO J 24 (2005) 3917-3926
7. Gong Y., Lee J.N., Brown M.S., Goldstein J.L., and Ye J. Juxtamembranous aspartic acid in Insig-1 and Insig-2 is required for cholesterol homeostasis. Proc Natl Acad Sci U S A 103 (2006) 6154-6159
8. Eberle D., Hegarty B., Bossard P., Ferre P., and Foufelle F. SREBP transcription factors: master regulators of lipid homeostasis. Biochimie 86 (2004) 839-848
9. Yokoyama C., Wang X., Brigs M.R., Admon A., Wu J., Hua X., et al. SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene. Cell 75 (1993) 187-197
10. Istvan E. Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Am Heart J 144 (2002) S27-S32
11. Chasman D.I., Posada D., Subrahmanyan L., Cook N.R., Stanton V.P., and Ridker P.M. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 291 (2004) 2821-2827
12. Schmitz G., Schmitz-Madry A., and Ugocsai P. Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy. Curr Opin Lipidol 18 (2007) 164-173
13. Sorkin S.C., Forestiero F.J., Hirata M.H., Guzman E.C.R., Cavalli S.A., Bertolami M.C., et al. APOAI polymorphisms are associated with variations in serum triglyceride concentrations in hypercholesterolemic individuals. Clin Chem Lab Med 43 (2005) 1339-1345
14. Salazar L.A., Hirata M.H., Quintao E.C., and Hirata R.D. Lipid-lowering response of the HMG-CoA reductase inhibitor fluvastatin is influenced by polymorphisms in the low-density lipoprotein receptor gene in Brazilian patients with primary hypercholesterolemia. J Clin Lab Anal 14 (2000) 125-131
15. Guzman E.C., Hirata M.H., Quintao E.C., and Hirata R.D. Association of the apolipoprotein B gene polymorphism with cholesterol levels and response so fluvastain in Brazilian individuals with high risk for coronary heart disease. Clin Chem Lab Med 38 (2000) 731-736
16. Vedie B., Jeunemaitre X., Megnien J.L., Atger V., Simon A., and Moatti N. A new DNA polymorphism in the 5′unstranslated region of the human SREBF-1a is related to development of the atherosclerosis in high cardiovascular risk population. Atherosclerosis 154 (2001) 589-597
17. Salek L., Lutucuta S., Ballantyne C.M., Gotto Jr. A.M., and Marian A.J. Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin. J Mol Med 80 (2002) 737-744
18. Fiegenbaum M., Silveira F.R., Van der Sand C.R., Van der Sand L.C., Ferreira M.E., Pires R.C., et al. Determinants of variable response to simvastatin treatment: the role of common variants of SCAP, SREBF-1a and SREBF-2 genes. Pharmacogenomics J 5 (2005) 359-364
19. Iwaki K., Nakajima T., Ota N., and Emi M. A common Ile796Val polymorphism of the human SREBP cleavage-activating protein (SCAP) gene. J Hum Genet 44 (1999) 421-422
20. Fan Y.M., Laaksonen R., Janatuinen T., Vesaleinen R., Nuutila P., Knuuti J., et al. Effects of pravastatin therapy on serum lipids and coronary reactivity are not associated with SREBP cleavage-activating protein polymorphism in healthy young men. Clin Genet 60 (2001) 319-321
21. Wibaut-Berlaimont V., Randi A.M., Mandryko V., Lunnon M.W., Haskard D.O., and Naoumova R.P. Atorvastatin affects leukocyte gene expression in dyslipidemia patients: in vivo regulation of homeostasis, inflammation and apoptosis. J Thromb Haemost 3 (2005) 677-685
22. Rodrigues A.C., Curi R., Britto L.R., Rebbechi I.M., Hirata M.H., Bertolami M.C., et al. Down-regulation of ABCB1 transporter by atorvastatin in a human hepatoma cell line and in human peripheral blood mononuclear cells. Biochim Biophys Acta 1760 (2006) 1866-1873
23. Kang J.G., Patino W.D., Matoba S., and Hwang P.M. Genomic analysis of circulating cells: a window into atherosclerosis. Trends Cardiovasc Med 16 (2006) 163-168
24. Lichtenstein A.H., Appel L.J., Brands M., Carnethon M., Daniels S., Franch H.A., et al. Diet and Lifestyle Recommendations Revision 2006: a scientific statement from the American Heart Association nutrition committee. Circulation 114 (2006) 82-96
25. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
26. Dobiasova M. Atherogenic index of plasma [log(triglycerides/HDL-cholesterol)]: theoretical and practical implications. Clin Chem 50 (2004) 1113-1115
27. Rasouli M., Kiasari A.M., and Mokhberi V. The ratio of apoB/apoAI, apoB and lipoprotein(a) are the best predictors of stable coronary artery disease. Clin Chem Lab Med 44 (2006) 1015-1021
28. Salazar L.A., Hirata M.H., Cavalli S.A., Machado M.O., and Hirata R.D. Optimized procedure for DNA isolation from fresh and cryopreserved clotted human blood useful in clinical molecular testing. Clin Chem 44 (1998) 1748-1750
29. Massirer K.B., Hirata M.H., Silva A.E., Ferraz M.L., Nguyen N.Y., and Hirata R.D. Interferon-alpha receptor 1 mRNA expression in peripheral blood mononuclear cells is associated with response to interferon-alpha therapy of patients with chronic hepatitis C. Braz J Med Biol Res 37 (2004) 643-647
30. -ΔΔCt method. Methods 25 (2001) 402-408
31. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29 (2001) e45
32. Rios D.L., Vargas A.F., Torres M.R., Zago A.J., Callegari-Jacques S.M., and Hutz M.H. Interaction between SREBP-1a and APOB polymorphisms influences total and low-density lipoprotein cholesterol levels in patients with coronary artery disease. Clin Genet 63 (2003) 380-385
33. Durst R., Jansen A., Erez G., Bravdo R., Butbul E., Ben Avi L., et al. The discrete and combined effect of SREBF-2 and SCAP isoforms in the control of plasma lipids among familial hypercholesterolaemia patients. Atherosclerosis 189 (2006) 443-450
34. Skarits C., Fischer S., and Haas O.A. Quantitation of the sterol regulatory element-binding protein mRNA in mononuclear blood cels by competitive RT-PCR. Clin Chim Acta 336 (2003) 27-37
35. Shimomura I., Shimano H., Horton J.D., Goldstein J.L., and Brown M.S. Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells. J Clin Invest 99 (1997) 838-845
36. Brown J.L., Feramisco J.D., Brown M.S., and Goldstein J.L. Cholesterol addition to ER membranes alters conformation of SCAP, the SREBP escort protein that regulates cholesterol metabolism. Mol Cell 10 (2002) 237-245
37. Roglans N., Verd J.C., Peris C., Alegret M., Vazquez M., Adzet T., et al. High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production. Lipids 37 (2002) 445-454
38. Densupsoontorn N., Worgall T.S., Seo T., Hamai H., and Deckelbaum R.J. Fatty acid supplied as triglyceride regulates SRE-Mediated gene expression as efficiently as free fatty acids. Lipids 42 (2007) 885-891
39. Zhang C., Shin D.J., and Osborne T.F. A simple promoter containing two Sp1 sites controls the expression of sterol-regulatory-element-binding protein 1a (SREBP-1a). Biochem J 386 (2005) 161-168
40. Cao H., Miskie B.A., and Hegele R.A. Functional promoter polymorphism in SREBP cleavage-activating protein (SCAP). J Hum Genet 47 (2002) 492-496
41. Yabe D., Xia Z., Adams C.M., and Rawson R.B. Three Mutations in sterol-sensing domain of SCAP block interaction with insig and render cleavage insensitive to sterols. Proc Natl Acad Sci U S A 99 (2002) 16672-16677